What is the probability of acquiring HIV from menstrual blood?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

HIV Transmission Risk from Menstrual Blood

Exposure to menstrual blood from an HIV-infected source carries a substantial risk for HIV transmission and warrants consideration of post-exposure prophylaxis (nPEP) within 72 hours if the source is known to be HIV-positive. 1

Risk Assessment Framework

The CDC guidelines classify blood exposure—including menstrual blood—among the highest-risk body fluids for HIV transmission 1. Menstrual blood is considered equivalent to regular blood for transmission purposes, as it contains:

  • HIV-infected blood cells
  • Cell-free HIV RNA
  • Potentially higher viral concentrations during menses

Specific Transmission Probability

While the guidelines don't provide exact per-act transmission probabilities specifically for menstrual blood exposure, they categorize blood exposures by route:

Per-act transmission risks from an HIV-positive source:

  • Blood transfusion: Highest risk (approaching 90%+)
  • Needle sharing/percutaneous injury: 0.23-0.67% per exposure
  • Receptive vaginal intercourse during menses: Higher than baseline vaginal intercourse (0.1-0.2%) 2
  • Mucous membrane exposure to blood: Substantial risk requiring nPEP consideration 1

Menstrual Cycle and Viral Shedding

Research demonstrates that HIV shedding in the female genital tract is highest during and immediately after menstruation 3, 4. Studies show:

  • 60% shedding frequency during follicular phase (post-menses)
  • HIV RNA levels peak during menses in cervicovaginal samples 4
  • Viral loads decline after menses until ovulation 3

Clinical implication: Sexual exposure during menstruation represents a higher-risk window for HIV transmission compared to other phases of the menstrual cycle.

Clinical Management Algorithm

Immediate Assessment (Within 72 Hours)

  1. Determine exposure characteristics:

    • Route: percutaneous (needlestick), mucous membrane contact, or sexual exposure
    • Volume and duration of contact
    • Integrity of exposed skin (intact vs. compromised)

  2. Assess source HIV status:

    • Known HIV-positive: Proceed with nPEP immediately 1
    • Unknown status from high-risk population: Start nPEP pending testing 1
    • Confirmed HIV-negative: No prophylaxis needed

  3. Initiate nPEP if indicated:

    • 28-day course of HAART (three-drug regimen preferred)
    • Must start within 72 hours; efficacy decreases significantly after 48 hours 1
    • Preferred regimens: efavirenz + lamivudine/emtricitabine + tenofovir, or lopinavir/ritonavir + zidovudine + lamivudine 1

Risk Stratification

Substantial risk requiring nPEP 1:

  • Percutaneous injury with menstrual blood from HIV+ source
  • Mucous membrane exposure (eyes, nose, mouth) to menstrual blood
  • Sexual intercourse during menstruation with HIV+ partner
  • Prolonged contact with large volume of menstrual blood on compromised skin

Lower risk (case-by-case evaluation):

  • Brief contact with intact skin
  • Small volume exposure
  • Source with undetectable viral load on ART (though nPEP still recommended if other high-risk factors present)

Critical Caveats

⚠️ Common pitfall: Assuming menstrual blood is less infectious than regular blood—this is incorrect. Treat all blood exposures equivalently.

⚠️ Timing is critical: The 72-hour window is firm. After this period, nPEP efficacy is questionable and risks may outweigh benefits 1.

⚠️ Co-infections matter: The presence of sexually transmitted infections increases HIV transmission risk substantially 1. Screen and treat accordingly.

⚠️ Viral load considerations: Recently infected individuals or those not on ART may have extremely high viral loads in blood and genital secretions, increasing transmission risk 1.

Additional Management

  • Wound care: Wash exposure site with soap and water immediately; flush mucous membranes with water 5
  • Baseline and follow-up HIV testing: At exposure, 6 weeks, 3 months, and 6 months 2
  • Screen for other bloodborne pathogens: Hepatitis B and C 1
  • Document exposure details thoroughly for medical-legal purposes 5

References

2
Guideline

sexually transmitted diseases treatment guidelines, 2015.

MMWR Recommendations and Reports, 2015

Related Questions

What is the HIV transmission risk per act of vaginal intercourse from an HIV-positive husband to his HIV-negative wife?
Can a child acquire HIV when the father is HIV-positive but the mother is HIV-negative?
What is the risk of HIV transmission after a solid (non‑hollow) needle exposure with no visible blood, and what post‑exposure prophylaxis is recommended?
Is HIV transmission possible when a band‑aid that briefly contacts microscopic blood from a finger is applied to a bleeding venipuncture site, and how does this risk compare to a needle‑stick exposure?
After how many days post‑exposure is the OraQuick rapid HIV test accurate?
How should postoperative hypotension after carotid endarterectomy be managed?
What is the appropriate management of a spider bite on the lower leg, including wound care, analgesia, tetanus update, and monitoring for necrosis or systemic toxicity?
When should a patient with carpal tunnel syndrome seek emergency department evaluation?
How should a 2-year-old child presenting with a dry cough and wheezing be managed?
What are the causes of a lateral anal fissure?
In hypertrophic obstructive cardiomyopathy causing shock, what is the pathophysiology and which first‑line, second‑line, and third‑line vasopressors should be used and why?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.